Cosentyx® (secukinumab) case studies: a decade of real-world clinical experience^1,2

Cosentyx is indicated for the treatment of: moderate to severe plaque psoriasis (PsO) in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis (PsA) in adults (alone or in combination with methotrexate [MTX]) who have responded inadequately to disease-modifying anti-rheumatic drug therapy.³

Cosentyx is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which Cosentyx is indicated.

Case study videos on demand

A decade of ... Looking to the future

Watch our latest recording featuring Professor Philip Conaghan as he takes us through one of his long-term patients with PsA, exploring key data and treatment decisions over the years.

Choose Cosentyx for your eligible patients, an IL-17A inhibitor with over a decade of experience and a consistent safety profile across indications^1–3

The most frequently reported adverse reactions are upper respiratory tract infections (17.1%) (most frequently nasopharyngitis, rhinitis).³

*Since first indication in 2015 for eligible adults with moderate to severe PsO.¹

Therapeutic Indications³
Cosentyx is indicated for the treatment of moderate to severe PsO in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active PsA in adult patients (alone or in combination with methotrexate [MTX]) when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate; active ankylosing spondylitis (AS) in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs; active moderate to severe HS (acne inversa) in adults with an inadequate response to conventional systemic HS therapy; active enthesitis-related arthritis (ERA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy; active juvenile psoriatic arthritis (JPsA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.³

AS, ankylosing spondylitis; ERA, enthesitis-related arthritis; HS, hidradenitis suppurativa; IL-17, interleukin 17A; JPsA, juvenile psoriatic arthritis; MTX, methotrexate; nr-axSpA, non-radiographic axial spondyloarthritis; PsA, psoriatic arthritis; PsO, psoriasis; SmPC, summary of product characteristics.

References

1. European Medicines Agency. Summary of positive opinion. EMA/CHMP/670627/2015. Available at: https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-cosentyx_en.pdf [Accessed July 2025]. 

2. European Medicines Agency. Assessment report: Cosentyx. EMA/CHMP/389874/2014. Available at: https://www.ema.europa.eu/en/documents/assessment-report/cosentyx-epar-public-assessment-report_en.pdf [Accessed July 2025]. 

3. Cosentyx® (secukinumab) Summary of Product Characteristics.

4. ClinicalTrials.gov. Secukinumab search results. Available at: https://www.clinicaltrials.gov/search?term=Secukinumab&aggFilters=status:com%20rec%20act [Accessed July 2025]. 

5. Novartis Data on File. Secukinumab (SEC018). February 2025.

UK | July 2025 | FA-11463462